EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LDL-Cholesterol Lowering Therapies: An Update

Robert Humphrey, Louise Bowman

British Journal of Hospital Medicine · 23.04.2026 · 87 (4)

DOI: 10.31083/bjhm53219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Hospital Medicine, online erschienen am 23.04.2026. Verfasst von Robert Humphrey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Service Unit, Oxford Population Health, University of Oxford, OX3 7LF Oxford, UK. Hauptthemen laut MEDLINE: Cholesterol, LDL, Anticholesteremic Agents, Hypercholesterolemia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-density lipoprotein-cholesterol (LDL-C) is a causal factor in atherosclerotic cardiovascular disease (ASCVD). Decades of genetic, epidemiological and randomised evidence support LDL-C reduction as a central strategy for cardiovascular risk reduction. Statins remain the first choice of LDL-C-lowering therapy due to their proven efficacy and favourable safety profile. However, therapeutic options have now expanded with widespread availability of other agents including ezetimibe, bempedoic acid and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These can be prescribed alone or in combination with statins to help achieve optimal LDL-C targets. More recently, RNA-based therapies, oral small molecule inhibitors, and gene-editing strategies have emerged, which may offer even greater LDL-C reduction. As evidence increasingly supports a “lower is better” approach, combining established and novel therapies offers opportunities to optimise ASCVD prevention. This review summarises the evolving landscape of LDL-C-lowering therapies, highlighting their mechanisms, evidence base, and implications for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLAnticholesteremic AgentsHypercholesterolemiaHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsDicarboxylic AcidsEzetimibeAtherosclerosisProprotein Convertase 9Fatty AcidsDrug Therapy, Combination

Stichwörter der Autor:innen

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitorsLDL-cholesterolPCSK9 inhibitorsezetimibehypercholesterolemiasmall interfering RNA

Substanzen

Cholesterol, LDLAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsDicarboxylic AcidsEzetimibe8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidPCSK9 protein, humanProprotein Convertase 9Fatty Acids

Autor:innen und Institutionen

  • Clinical Trial Service Unit, Oxford Population Health, University of Oxford, OX3 7LF Oxford, UK.

Zitieren

APA

Humphrey, R., & Bowman, L. (2026). LDL-Cholesterol Lowering Therapies: An Update. British Journal of Hospital Medicine, 87(4). https://doi.org/10.31083/bjhm53219

Vancouver

Humphrey R, Bowman L. LDL-Cholesterol Lowering Therapies: An Update. British Journal of Hospital Medicine. 2026;87(4). doi:10.31083/bjhm53219

BibTeX
@article{Humphrey2026,
  author = {Humphrey, Robert and Bowman, Louise},
  title = {LDL-Cholesterol Lowering Therapies: An Update},
  journal = {British Journal of Hospital Medicine},
  year = {2026},
  volume = {87},
  number = {4},
  doi = {10.31083/bjhm53219}
}
Kostenlos starten →